Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Chobei Takeda I

Bruno Villetelle

Takeda Pharmaceutical Company Limited

Intelligent Health organizes a healthtech summit that connects clinicians, technologists, and executives to discuss the use of AI in medicine. The summit aims to advance conversations and collaboration in the healthcare sector, focusing on innovations and solutions in health technology.

Intelligent Health

Solbosch provides a variety of medical and paramedical specialties. It is equipped with a viral air purifier.

Solbosch

Acerta Pharma, an affiliate of AstraZeneca, develops and delivers targeted novel transformational medicines for patients with hematological malignancies.  Acerta Pharma uses innovative approaches to discover, develop, and deliver targeted medicines, focusing on innovative clinical strategies and resistance biology.

Acerta Pharma

Takeda Oncology

BioLife Plasma Services

Takeda Canada Inc.

TAKEDA IBDpoint

Innovation Capability Center at Takeda

Dengue Academy

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society.We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities.

Metric
Company Name	Takeda Pharmaceutical Company Limited	Intelligent Health	Solbosch	Acerta Pharma
Symbol	4.50K
MSH ID	COM:TAKEDA	AI:INTELLIGENTHEALTH	BE:SOLBOSCH	COM:ACERTA-PHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Health Technology	Healthcare	Pharmaceutical
Country	JP	CH	BE	NL
Stage
Employee Count	49.28K
Website	takeda.com	intelligenthealth.ai	solbosch.be	acerta-pharma.com
LinkedIn	takeda-pharmaceuticals	intelligent-health-ai-ltd	le-solbosch
Founders

Metric
Market Cap	45.14B
Enterprise Value
Monthly Web Traffic	825.79K	1.45K
Web Traffic Growth	-0.01	-0.76
Valuation
Raised Capital	19.80M

Metric
Revenue	28.44B
Revenue (LTM)
Revenue (NTM)
Gross Profit	14.57B
EBITDA	7.53B
Operating Income	2.68B
Net Income	960.83M
EPS	0.61
Diluted EPS	0.61
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.68
Operating Profit Margin	0.08
EBITDA Margin	0.26
Net Profit Margin	0.04
Return on Equity	0.03
Return on Assets	0.01
Return on Capital Employed	0.03

COM:TAKEDA

Takeda Pharmaceutical Company Limited

Last Close

4,113.00

25/11 06:45

Market Cap

6.77T

Beta: -

Volume Today

9.61M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	36.83
P/B Ratio	0.97
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.66
EV Multiple	2.28

Metric
Days Sales Outstanding	65.06
Days Payables Outstanding	130.39
Days Inventory Outstanding	315.31
Operating Cycle	380.37
Cash Conversion Cycle	249.98
Asset Turnover	0.29

Metric
Operating Cash Flow	4.27B
Free Cash Flow	1.06B
Cash Flow to Debt	0.16
Operating Cash Flow/Sales	0.18
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	3.05B
Accounts Receivable	100.73M
Inventory	8.07B
Goodwill	36.08B
Debt to Capitalization	0.41
Debt to Assets	0.33
Current Ratio	1.06
Quick Ratio	0.74

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02
R&D to Revenue	0.17
SG&A to Revenue